510(k) device
Eeva System
Auxogyn, Inc. · Embryo Image Assessment System, Assisted Reproduction (PBH, Class II) · First FDA decision Nov 24, 2014, newest Nov 24, 2014Infertility
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
510(k) pathway
Device trials
7
Naming "Eeva"
MAUDE reports
0
Brand "Eeva", since 2015
PubMed studies
22
Mentioning "Eeva"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Eeva System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- EEVA SYSTEM510(k)
K142147 · Decided Nov 24, 2014 · 111 days after receipt
Device type: Embryo Image Assessment System, Assisted Reproduction (PBH) · Obstetrics & Gynecology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Eeva", any status and sponsor, newest update first.
- TICON-Day 3, Time Lapse Versus Conventional Method in Day 3 Embryo Culture and AssessmentPivotal-lookingTerminated
Merck KGaA, Darmstadt, GermanyNot on our public-company list
NCT03164551 · 408 participants · Start Apr 16, 2018 · Primary completion Nov 20, 2019
Device: GERI+ incubator; Conventional incubator · For: Infertility
Sites: Calgary, Canada; Skive, Denmark; Clamart, France · 17 sites in all
- TiLE (Time Lapse Eeva) Clinical TrialPivotal-lookingCompleted
Merck KGaA, Darmstadt, GermanyNot on our public-company list
NCT02417441 · 976 participants · Start Jun 29, 2015 · Primary completion Feb 9, 2017
Device: Eeva · For: Fertility
Sites: Calgary, Canada; Burlington, Canada; Mississauga, Canada · 23 sites in all
- Eeva™ Pregnancy Pilot Study (PPS)Pivotal-lookingStatus unknown
Progyny, Inc.Not on our public-company list
NCT02218255 · 240 participants (planned) · Start Aug 2014 · Primary completion Mar 2016
Device: Eeva™ results · For: Infertility
Sites: Boston, Massachusetts
4 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Eeva", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code PBH
1 reports: 1 malfunction, 0 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Eeva"[tiab]. The summary above synthesizes these.
- Protective effect of Vernonia amygdalina Delile against doxorubicin-induced cardiotoxicity.
Syahputra RA, Harahap U, Dalimunthe A, et al. · Heliyon · 2021
- Embryo morphokinetic score is associated with biomarkers of developmental competence and implantation.
Coticchio G, Pennetta F, Rizzo R, et al. · J Assist Reprod Genet · 2021
- Assessment of Frailty by the French Version of the Vulnerable Elders Survey-13 on Digital Tablet: Validation Study.
Zolnowski-Kolp V, Um Din N, Havreng-Théry C, et al. · J Med Internet Res · 2023
- Evaluation of anti-inflammatory and anti-oxidant potential of seed extracts of Vernonia anthelmintica.
Jamil S, Khan RA, Ahmed S, et al. · Pak J Pharm Sci · 2017
- Prospective study of automated versus manual annotation of early time-lapse markers in the human preimplantation embryo.
Kaser DJ, Farland LV, Missmer SA, et al. · Hum Reprod · 2017Research Support, Non-U.S. Gov't
- Impact of the addition of Early Embryo Viability Assessment to morphological evaluation on the accuracy of embryo selection on day 3 or day 5: a retrospective analysis.
Revelli A, Canosa S, Carosso A, et al. · J Ovarian Res · 2019
- A pilot randomized controlled trial of Day 3 single embryo transfer with adjunctive time-lapse selection versus Day 5 single embryo transfer with or without adjunctive time-lapse selection.
Kaser DJ, Bormann CL, Missmer SA, et al. · Hum Reprod · 2017Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Outcome of in vitro fertilization cycles with automatic time-lapse instrumentation combined with the early embryo viability assessment score.
Kokunai K, Yamashita Y, Inoue T, et al. · J Obstet Gynaecol Res · 2021
- Embryo selection using time-lapse analysis (Early Embryo Viability Assessment) in conjunction with standard morphology: a prospective two-center pilot study.
Kieslinger DC, De Gheselle S, Lambalk CB, et al. · Hum Reprod · 2016Multicenter Study, Observational Study
- Clinical outcomes of uninterrupted embryo culture with or without time-lapse-based embryo selection versus interrupted standard culture (SelecTIMO): a three-armed, multicentre, double-blind, randomised controlled trial.
Kieslinger DC, Vergouw CG, Ramos L, et al. · Lancet · 2023Randomized Controlled Trial, Multicenter Study
- Eeva Jalavisto. 1909-1966.
Holmberg PC · Gerontologia · 1968Biography, Historical Article
- Phytochemistry, Brine shrimp lethality and mice acute oral toxicity studies on seed extracts of Vernonia anthelmintica.
Jamil S, Khan RA, Afroz S, et al. · Pak J Pharm Sci · 2016
Other devices of this type
Also filed under product code PBH.
- Magenta BlastFuture Fertility, Inc. · 510(k) 2026
- Embryo PredictAlife Health · 510(k) 2026
- Chloe BlastFairtility , Ltd. · 510(k) 2025
- KIDScore D3Vitrolife A/S · 510(k) 2019
- Eeva 2.0Auxogyn, Inc. · De Novo 2014
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.